

1 ***Jasonia glutinosa* (L.) DC., a traditional herbal medicine, reduces inflammation, oxidative stress and**  
2 **protects the intestinal barrier in a murine model of colitis**

3  
4 Marta Sofía Valero<sup>1,2\*</sup>, Mateo González<sup>3</sup>, Mariano Ramón Gimenez<sup>3</sup>, Paula B. Andrade<sup>4</sup>, Eduardo Moreo<sup>5</sup>,  
5 Francisco Les<sup>3</sup>, Fátima Fernandes<sup>4</sup>, Carlota Gómez-Rincón<sup>3</sup>, César Berzosa<sup>3</sup>, José Antonio García de Jalón<sup>6</sup>,  
6 M<sup>a</sup> Pilar Arruebo<sup>1,2</sup>, Miguel Ángel Plaza<sup>1,2</sup>, Ralf Köhler<sup>7</sup>, Víctor López<sup>2,3\*</sup>, Patricia Valentão<sup>4</sup>, Marta  
7 Castro<sup>1,2</sup>

8  
9 <sup>1</sup>Departamento de Farmacología y Fisiología, Universidad de Zaragoza, Zaragoza, Spain. Instituto de  
10 Investigación Sanitaria Aragón (IIS Aragón). Zaragoza, Spain.

11 <sup>2</sup>Instituto Agroalimentario de Aragón, IA2, Universidad de Zaragoza-CITA, Zaragoza, Spain.

12 <sup>3</sup>Facultad de Ciencias de la Salud, Universidad San Jorge, Villanueva de Gállego (Zaragoza), Spain.

13 <sup>4</sup>REQUIMTE/LAQV, Laboratório de Farmacognosia, Departamento de Química, Faculdade de Farmácia,  
14 Universidade do Porto, Rua de Jorge Viterbo Ferreira n.º 228, Porto 4050-313, Portugal

15 <sup>5</sup>Grupo de Genética de Micobacterias. Dpto. Microbiología, Medicina Preventiva y Salud Pública.  
16 Universidad de Zaragoza, Zaragoza, Spain.

17 <sup>6</sup>Departamento de Patología Animal, Universidad de Zaragoza, Zaragoza, Spain.

18 <sup>7</sup>Instituto de Investigación Sanitaria Aragón (IIS Aragón). Zaragoza, Spain. Aragon Agency for Research  
19 and Development (ARAID), Zaragoza, Spain.

20  
21 \*Corresponding authors:

22 Marta Sofía Valero (msvalero@unizar.es, +34-974 239 408)

23 Víctor López (ilopez@usj.es, +34 976 060 100)

41 **Abstract**

42 *Jasonia glutinosa* (L.) DC., known as rock tea (RT), is traditionally used in Spain as a digestive due to its  
43 beneficial properties in bowel disorders. The pharmacological nature of these properties has not been  
44 established yet. The aim of this work was to evaluate the therapeutic utility of RT in experimental colitis  
45 and to identify chemical constituents with anti-inflammatory and/or anti-oxidative properties.

46 RT extract was prepared with ethanol in a Soxhlet apparatus and analysed by HPLC-DAD. Superoxide  
47 radical scavenging properties, xanthine oxidase and lipoxygenase (5-LOX) inhibitory activity, and  
48 capability to lower nitric oxide (NO) and tumour necrosis factor  $\alpha$  (TNF- $\alpha$ ) levels were measured in cell-  
49 free and cell-based assays. In the 2.5%-dextran-sodium sulphate (DSS) injury-repair model of ulcerative  
50 colitis (UC), mice were daily treated with sulfasalazine (SSZ, as reference drug, 100 mg/kg bw), RT (5, 25  
51 and 50 mg/kg bw, p.o.), or vehicle over 20-days. Colitis was scored daily. Colon samples were  
52 macroscopically and histopathologically examined. Protein levels of myeloperoxidase (MPO), interleukins  
53 6, and 10 (IL-6, IL-10), inducible NO synthase (iNOS), and cyclooxygenase-2 (COX-2) were studied as  
54 markers of oxidative stress and inflammatory activity. The integrity of the apical epithelial layer was  
55 assessed by immunofluorescence staining of zonula occludens-1 (ZO-1). Finally, intestinal contractility was  
56 also evaluated by isometric myography.

57 Fifteen phenolic compounds and three pigments were identified and quantified, of which caffeoylquinic  
58 acids, and the flavonoid, quercetin-3-O-galactoside, were the most abundant. RT extract significantly  
59 scavenged superoxide radicals, inhibited 5-LOX activity, and lowered NO and TNF- $\alpha$  levels. DSS-treated  
60 mice receiving RT scored clinically lower than controls during the first 3-days of DSS-treatment and during  
61 the recovery period. SSZ was less effective than RT. Anatomical and histological examination of colon  
62 samples revealed that RT significantly prevented shortening and thickening, and lowered the macroscopic  
63 damage score. RT also significantly prevented the increase of MPO activity, IL-6 levels, iNOS and COX-  
64 2 expression, the loss of ZO-1 apical expression, and normalized contractility disturbances.

65 In conclusion, daily administration of RT showed therapeutic properties in the DSS-model of UC. The  
66 benefits of RT can likely be attributed to its anti-inflammatory and antioxidant phenolic and flavonoid  
67 constituents.

68

69 **Keywords list:** inflammation; murine; polyphenols; rock tea; ulcerative colitis; ethnopharmacology

70

71 **List of abbreviations**

72 ACh: acetylcholine, AUC: area under the curve, COX-2: cyclooxygenase-2, CV: coefficient of variation,  
73 DAI: disease activity index, DMSO: dimethyl sulfoxide, DSS: dextran sodium sulphate, HE: haematoxylin-  
74 eosin, HPLC-DAD: high pressure liquid chromatography coupled to a diode-array detector, iNOS:  
75 inducible nitric oxide synthase, IBD: inflammatory bowel disease, IL-6: interleukin 6; IL-10: interleukin  
76 10, LOD: limit of detection, LOQ: limit of quantification, 5-LOX: 5-lipoxygenase, LPS:  
77 lipopolysaccharide, MPO: myeloperoxidase, NADH/PMS:  $\beta$ -nicotinamide adenine dinucleotide/phenazine  
78 methosulfate, NBT: nitrotetrazolium blue chloride, NO: nitric oxide,  $O_2^{\cdot-}$ : superoxide radical, RT: rock tea,  
79 SSZ: sulfasalazine, TNF- $\alpha$ : tumour necrosis factor-alpha, UC: ulcerative colitis, X/XO: xanthine/xanthine  
80 oxidase, ZO-1: zonula occludens-1.

81

## 82 **1. Introduction**

83 Ulcerative colitis (UC) is an inflammatory bowel disease (IBD), which is characterized by inflammation of  
84 the intestinal wall and ulcers in colon and rectum. The prevalence and incidence of UC is increasing over  
85 the years (Molodecky et al. 2012). The classical clinical features are weight loss, bloody stool, abdominal  
86 pain and intestinal motility disorders as diarrhoea or tenesmus. The aetiology is not fully understood,  
87 although genetic and environmental factors have been proposed (Baumgart and Carding 2007; Baumgart  
88 and Sandborn 2007; Danese and Fiocchi 2011; Low et al. 2013). The main histopathological feature of UC  
89 is the damage of the intestinal mucosa (epithelial layer), resulting in a loss of the defensive epithelial barrier,  
90 leading to increased permeability and an inflammatory response (Silva et al. 2016). Under inflammatory  
91 conditions, the morphology and structure of interstitial cells of Cajal can be affected, producing changes in  
92 the gastrointestinal motility (Dai et al. 2017; Won et al. 2006). In addition, dysmotility can increase the  
93 overgrowth of bacteria, the release of toxic products as well as their translocation through the barrier of the  
94 intestinal mucosa, increasing the severity of the condition.

95 Currently, drug therapies for UC based on salicylates and corticosteroids are not satisfactory, can be costly  
96 and may have important side effects. Therefore, there is a clinical need for new therapeutic strategies that  
97 may also derive from traditional herbal medicine (Low et al. 2013; Zheng et al. 2017).

98

99 *Jasonia glutinosa* (L.) DC. (Compositae), popularly known as rock tea (RT), is a medicinal plant species  
100 of the Iberian Peninsula and southern France. Infusions and decoctions are described as digestives and are  
101 used as substitutes for coffee or tea after meals due to the fact that this medicinal plant has been reported to  
102 relieve common gastrointestinal disturbances, such as diarrhoea or abdominal pain (Alarcón et al. 2015;  
103 Pardo Santayana and Morales 2004). Other traditional uses include the treatment of appendicitis, respiratory  
104 diseases and as analgesic, antiemetic or antidepressant medicinal plant (Akerreta et al. 2007; Pardo  
105 Santayana and Morales 2004).

106 Although certain studies with *J. glutinosa* have shown antioxidant (López et al. 2008), anti-inflammatory  
107 (Bermejo et al. 2002), antimicrobial (Villaescusa-Castillo et al. 2000; Villaescusa et al. 1996),  
108 antihypertensive (Valero et al. 2015) and spasmolytic properties (Castro et al. 2016), there is still a  
109 considerable lack of *in-vivo* studies supporting these traditional uses. In fact, studies involving the effects  
110 of this medicinal plant on the clinical symptoms of intestinal inflammation have never been performed or  
111 published. To the best of our knowledge, most of the existing studies concerning the chemical composition  
112 of *J. glutinosa* focus on its volatile composition (Valero et al. 2013). Although previous works report the  
113 presence of some flavonoids (Rubio et al. 1995; Villaescusa et al. 1995), there is a gap in the biologically-  
114 relevant metabolites knowledge of this plant. Therefore, we here aim to examine whether oral  
115 administration of RT extract is beneficial in the standard dextran sodium sulphate (DSS)-model of colitis.  
116 So, we evaluated the efficacy of RT to ameliorate the clinical progression of colitis, the microscopic and  
117 macroscopic colonic damage, loss of intestinal barrier and motility disturbances as well as its antioxidant  
118 and anti-inflammatory properties. Phenolic and carotenoid profiles were also determined by liquid  
119 chromatography (HPLC-DAD), in an attempt to identify therapeutically active constituents.

120

## 121 **2. Materials and Methods**

### 122 **2.1. Standards and reagents**

123 Standards of ascorbic acid, linoleic acid, caffeic acid, quercetin, lutein,  $\beta$ -carotene, chlorophyll *a*, and  
124 chlorophyll *b* were purchased from Sigma-Aldrich (St. Louis, MO, USA). Quercetin-3-*O*-galactoside,  
125 quercetin-3-*O*-glucoside, kaempferol and isorhamnetin were from Extrasynthèse (Genay, France). 3-*O*-  
126 caffeoylquinic acid, 5-*O*-caffeoylquinic acid, 4-*O*-caffeoylquinic acid, 1,3-di-*O*-caffeoylquinic acid,  
127 isoferulic acid, 3,4-di-*O*-caffeoylquinic acid, 3,5-di-*O*-caffeoylquinic acid, 1,5-di-*O*-caffeoylquinic acid,  
128 and 4,5-dicaffeoylquinic acid were obtained from Chengdu Biopurify Phytochemicals Ltd. (Chengdu,  
129 Sichuan, China). Pheophytin *a* was from LGC Standards (Irvine, CA, US).

130 Potassium dihydrogen phosphate ( $\text{KH}_2\text{PO}_4$ ), sodium phosphate dibasic ( $\text{Na}_2\text{HPO}_4$ ), nitrotetrazolium blue  
131 chloride (NBT), lipoxygenase (5-LOX) from *Glycine max* (L.) Merr. (type V-S; EC 1.13.11.12),  $\beta$ -  
132 nicotinamide adenine dinucleotide (NADH), phenazine methosulfate (PMS), *tert*-butyl methyl ether  
133 (MTBE), gallic acid, xanthine, NBT, xanthine oxidase, DPPH, galantamine, ATCI, DTNB, Tris, vanillic  
134 acid, 4-aminoantipyrine, horseradish peroxidase, LPS (lipopolysaccharide from *Escherichia coli* serotype  
135 011:B4), RPMI Medium 1640-GlutaMAX™-I, trypsin, penicillin G, streptomycin, dimethyl sulfoxide  
136 (DMSO), sodium nitrite ( $\text{NaNO}_2$ ), compounds of Griess reactive and acetylcholine were purchased from  
137 Sigma-Aldrich. HPLC grade methanol was obtained from Merck (Darmstadt, Germany) and formic acid  
138 was purchased from BDH Prolab (Dublin, Ireland). Dextran sodium sulphate (DSS) was purchased from  
139 Panreac.

140 Water was deionized in a Milli-Q water purification system (Millipore, Bedford, MA, USA).

### 141 **2.2. Plant material and extraction**

142 Collection of the plant and preparation of the ethanolic extract were performed as described in Valero *et*  
143 *al.*, (Valero et al. 2015) following The United Nations Convention on Biological Diversity. Samples were  
144 authenticated and a voucher specimen (ref. 001-2012) has been deposited at the Department of Pharmacy  
145 of Universidad San Jorge. Solvent (ethanol) was removed using a rotary evaporator under vacuum and  
146 samples were kept at  $-20^\circ\text{C}$  until bioassays.

### 147 **2.3. Phytochemical analyses**

#### 148 **2.3.1. HPLC-DAD analysis**

149 The dried ethanolic extract of *J. glutinosa* was reconstituted in high quality methanol and filtered with a  
150 membrane (pore size:  $0.45\ \mu\text{m}$ ) before chromatographic analysis.

##### 151 **2.3.1.1. Phenolic compounds determination**

152  $20\ \mu\text{L}$  of re-dissolved and filtered extract was analysed using a Gilson HPLC-DAD unit with a Spherisorb  
153 ODS2 column ( $25.0\ \text{cm}\times 0.46\ \text{cm}$ ,  $5\ \mu\text{m}$  particle size; Waters, Milford, MA, USA) maintained at  $26^\circ\text{C}$ .  
154 The mobile phase solvents consisted of 1% (v/v) formic acid in water (eluent A) and methanol (eluent B)  
155 and a gradient program was used as follows: from 10 to 15% B (5 min), from 15 to 40% B (20 min), from  
156 40 to 55% B (25 min), from 55 to 100% B (10 min), 100% B isocratic (20 min) run at a flow rate of  $0.4$   
157  $\text{mL}/\text{min}$ . Spectral data from all peaks (200-600 nm) and chromatograms (280, 320, 330 nm) were collected  
158 using an Agilent 1100 series diode array detector. Retention times and UV-vis spectra of authentic standards  
159 analysed in the same conditions were used for the identification of phenolic compounds. For quantification  
160 purposes, the extract was injected in triplicate. The amount of phenolic compounds present in the extract

161 was achieved from the calibration curves of the respective authentic standard analysed under the same  
162 conditions (Table 1).

163 The linearity range of the method was assessed by building calibration curves using, at least, six different  
164 concentration levels of the analytes, according to the range of concentrations found in the sample. The limit  
165 of detection (LOD) and limit of quantification (LOQ) were determined from calibration curve data,  
166 following the formula:

$$167 \text{ LOD} = (3 \times SD)/b$$

$$168 \text{ LOQ} = (10 \times SD)/b,$$

169 where *SD* is the residual standard deviation and *b* is the slope. The repeatability and reproducibility of the  
170 method were calculated in terms of intra-day and inter-day precision, respectively. Repeatability was  
171 performed by injecting the *J. glutinosa* extract, by the same analyst, 5 times in the same day, whereas,  
172 reproducibility was performed by injecting that same sample in triplicate during 5 consecutive days. Final  
173 results were expressed as coefficient of variation (CV, %) (Table 1).

#### 174 **2.3.1.2. Pigments (carotenoids and chlorophylls) determination**

175 20 µL of re-dissolved and filtered ethanolic extract was analysed using a Gilson HPLC unit with a C30  
176 YMC carotenoid column 5 µm, 250 × 4.6 mm (YMC, Japan) maintained at 26 °C, following the procedure  
177 described by Amaro *et al.*, (Amaro *et al.* 2015) with some modifications. The mobile phase was composed  
178 by two solvents, methanol (A) and tert-butyl methyl ether (B); elution started with 95% A and used a  
179 gradient to obtain 70% at 30 min, 50% at 50 min, 0% at 60 min, 0% isocratic at 65 min and 95% at 70 min.  
180 In this case, spectral data from all peaks (200-700 nm) and chromatograms at 450 nm were collected using  
181 an Agilent 1100 series diode array detector. The data were processed with Clarity Software, version  
182 5.04.158 (DataApex Ltd, Prague, Czech Republic). Peak purity was checked by the software contrast  
183 facilities. The extract was injected in triplicate. The amount of pigments was calculated using external  
184 calibration curves. Only the compounds, for which we had reference standards, were quantified. The  
185 linearity range, the LOD and LOQ, the repeatability and reproducibility of the method (Table 1) were  
186 determined according to the one described above.

### 187 **2.4. Cell-free assays**

#### 188 **2.4.1. Antioxidant activity**

##### 189 **2.4.1.1. Non-enzymatic assay**

190 According to a procedure previously documented, the NADH/PMS system was used for the generation of  
191 superoxide radicals (Valentão *et al.* 2001). Due to the low solubility of the extract in the phosphate buffer  
192 (19 mM, pH 7.4), we used a non-interfering DMSO percentage (1% *v/v*, phosphate buffer). The remaining  
193 components were dissolved in phosphate buffer. Antiradical activity was determined  
194 spectrophotometrically at 562 nm, in a 96-well Multiskan Ascent plate reader (Thermo; electron  
195 corporation), working in kinetic mode, by monitoring the effect of extract on reduction of NBT induced by  
196 superoxide radical. Four independent assays were performed in triplicate and quercetin as positive control.

##### 197 **2.4.1.2. Enzymatic assay**

198 The xanthine/xanthine oxidase (X/XO) system was used for the enzymatic generation of superoxide  
199 radicals (Rodríguez-Chávez *et al.* 2015). The assay was performed in 96-well microplates, and the mixture  
200 contained 90 µM xanthine, 16 mM Na<sub>2</sub>CO<sub>3</sub> and 22.8 µM NBT dissolved in phosphate buffer (pH 7). Then,

201 30  $\mu$ L of sample at different concentrations (0.0125, 0.0039, 0.0020, 0.0010, 0.0005, 0.0002, 0.0001,  
202 0.00006, 0.00003 mg/mL) and 30  $\mu$ L of 168 U/L xanthine oxidase were added to start the reaction.  
203 Incubation time: 2 min at 37 °C. Absorbance was measured at 560 nm. Gallic acid was used as reference.  
204 The effect on xanthine oxidase was also evaluated by measuring the formation of uric acid from xanthine  
205 at 295 nm after 2 min. The reaction mixture contained the same components as described above in the  
206 xanthine/xanthine oxidase system but the reaction mixture did not contain 22.8  $\mu$ M NBT.

## 207 **2.4.2. Anti-inflammatory activity**

### 208 **2.4.2.1. 5-Lipoxygenase inhibition**

209 The inhibitory effect on 5-LOX was assessed in 96-well plates, using a procedure previously described by  
210 Barbosa *et al.*, (Barbosa *et al.* 2017). A Synergy™ HT microplate reader (Biotek Instruments; Winooski,  
211 USA) was used to detect 5-LOX inhibitors at 234 nm for 3 min. 5-LOX inhibition was calculated as follows:  
212 LOX inhibitory activity (%) =  $100 \times [1 - (\text{mean V of sample} / \text{mean V of control})]$ , where mean V  
213 corresponds to the mean velocity of kinetic well analysis. Six independent assays were performed in  
214 triplicate. Quercetin was used as positive control.

## 215 **2.5. Cell-based assays**

### 216 **2.5.1. Cell culture conditions**

217 Murine macrophages (J774.2; The Agrifood Research and Technology Centre of Aragon; Zaragoza, Spain)  
218 were cultured in 96-well plates with Roswell Park Memorial Institute 1640 Medium (RMPI 1640 medium,  
219 GlutaMAX™ Supplement) containing 10% Fetal Bovine Serum, 100 U/mL penicillin G and 100  $\mu$ g/mL  
220 streptomycin. Cells were seeded in 96 well microplates at a density of  $10^3$  cell/well and incubated at 37 °C  
221 in a humidified incubator.

### 222 **2.5.2. NO levels**

223 Nitrite content in culture medium was measured as an indicator of nitric oxide (NO) production. Nitrites  
224 were measured at 24 h after the addition of different concentration of RT extract (23, 47 or 93  $\mu$ g/mL) and  
225 LPS (1  $\mu$ g/ml) for 30 minutes. The same volume of supernatant and the Griess reagent (1% sulfanilamide  
226 in 5% phosphoric acid and 0.1% naphthylethylenediamine dihydrochloride in distilled water) were mixed  
227 during 10 minutes at room temperature and the absorbance at 570 nm was determined with a plate reader.

### 228 **2.5.3. TNF- $\alpha$ levels**

229 For determination of tumour necrosis factor-alpha (TNF- $\alpha$ ) levels, cells were incubated with various  
230 concentrations of RT extract (23, 93  $\mu$ g/mL) and LPS (1  $\mu$ g/ml)-stimulated for 30 minutes. After  
231 centrifugation, the obtained supernatant was used to calculate the amount of TNF- $\alpha$  by a standard sandwich  
232 ELISA kit specific for murine cytokines (Cayman chemical®).

## 233 **2.6. In vivo assays**

### 234 **2.6.1. Animals**

235 Male C57BL/6 mice (8-12 weeks) were purchased from Janvier (LeGenest St. Isle, France) and were  
236 allowed to acclimate for 1 week prior to the experiments. The animals were housed in plastic cages, 4-5  
237 mice/cage, under normal laboratory conditions ( $20 \pm 2$  °C, 40-60% relative humidity and normal light/dark-  
238 cycle) with free access to standard chow and water.

239 All the procedures of this study were performed in accordance with the ARRIVE guidelines and the Ethics  
240 Advisory Commission for Animal Experimentation of Universidad de Zaragoza (PI66/14, Spain).

241 **2.6.2. Treatment, experimental colitis induction and tissue collection**

242 Animals were randomly divided into seven groups. i) control group (n=15); ii) RT<sub>50</sub> group (n=8); iii)  
243 water+DSS group (n=15); iv) RT<sub>5</sub>+DSS group (n=4); v) RT<sub>25</sub>+DSS group (n=4); vi) RT<sub>50</sub>+DSS group  
244 (n=15) and vii) sulfasalazine (SSZ) + DSS group (n=12). All groups daily received 200 µL of water (control  
245 or water+DSS groups), RT extract (5, 25 or 50 mg/kg bw: RT<sub>5</sub>+DSS groups, RT<sub>25</sub>+DSS groups, RT<sub>50</sub> or  
246 RT<sub>50</sub>+DSS groups) or SSZ (100 mg/kg bw) by oral gavage over a 20-day period according to Castro et al.,  
247 2016 (Castro et al. 2016). The dose of SSZ has been chosen according to previous studies (Kim et al. 2014;  
248 Singh et al. 2009). RT and SSZ solutions were prepared daily. In order to avoid the undesirable effects of  
249 coprophagy, all the animals housed in each cage received the same treatment.

250 An injury-repair colitis model was used (Whittem et al. 2010). At day 11, colitis was induced by switching  
251 to a 2.5% (w/v) solution of DSS (MW: 40,000 Da, Panreac, Lörrach, Germany) as drinking solution for 7  
252 days, followed by 3 days of autoclaved tap water for the recovery (Low et al. 2013). At day 20, all animals  
253 were sacrificed via cervical dislocation and the colon was removed for macroscopic study (Figure 3a).  
254 Terminal ileum was extracted and kept in cold Ringer Krebs (in mM: NaCl 120, KCl 4.70, CaCl<sub>2</sub> 2.40,  
255 MgSO<sub>4</sub> 1.20, NaHCO<sub>3</sub> 24.50, KH<sub>2</sub>PO<sub>4</sub> 1.00 and glucose 5.60; pH 7.4) for organ bath studies. Finally,  
256 samples of colon of control, RT<sub>50</sub> group, water+DSS and RT<sub>50</sub>+DSS animals were kept for  
257 histopathological, immunofluorescence, myeloperoxidase (MPO), interleukins 6 and 10 (IL-6, IL-10),  
258 inducible nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2) studies.

259 **2.6.3. Colitis assessment**

260 A disease activity index (DAI) was used to assess the DSS-induced colitis symptomatology. DAI was  
261 calculated as the sum of the body weight score, which was the percentage of weight loss from the initial  
262 body weight on every day (0: < 1%, 1: 1-5%, 2: 5-10%, 3: 10-15%, 4: ≥15%), changes in stool consistency  
263 (0: normal, 1: loose stool, 4: water diarrhoea) and presence of faecal blood (0: normal, 2: occult bleeding,  
264 4: visible bleeding). The occult blood was measured with a stool blood test (Tri Slider FOB Guayaco,  
265 Sanilabo, Spain).

266 **2.6.4. Macroscopic study**

267 Colon length and thickness of the proximal and distal colonic wall were determined using a digital Vernier  
268 calliper (0.01 mm of resolution). Thereafter, the colon was cut-open longitudinally and washed with 0.9%  
269 saline solution. Colitis signs was graded according to a standard scoring system: Number of adhesions (0:  
270 0, 1: 1, 2: 2, 3: >2), diarrhoea (0: normal, 1: loose stool, 4: water diarrhoea), tumefaction (0: absence, 1:  
271 moderate, 2: severe), stenosis (0: 0, 1: 1, 2: 2, 3: >2), mucus (0: absence, 1: presence), haemorrhage (0:  
272 absence, 1: manifest bleeding), erythema (0: no macroscopic changes, 1: <1 cm, 2: ≥1 cm), ulcers or  
273 erosions (0: 0, 1: <1 cm, 2: ≥1 cm) and occult blood (0: no, 1: yes). A total macroscopic damage score was  
274 calculated for each animal.

275 **2.6.5. Recording of intestinal contractility**

276 Ileum was washed with Ringer Krebs, freed from adipose and connective tissues and cut in segments (10  
277 mm). The whole segments were suspended in the direction of longitudinal smooth muscle fibres in an organ  
278 bath in 5 mL of Ringer Krebs maintained at 37 °C and gassed with 95% O<sub>2</sub>-5% CO<sub>2</sub>. Intestinal contractility  
279 was recorded isotonicly as in previous works of our laboratory (Valero et al. 2011).

280 After an adaptation period, spontaneous contractions of each group were registered and the effect on  
281 contractility of acetylcholine (ACh, 100  $\mu$ M), a cholinergic agonist, was tested. To measure the irregularity  
282 of contractions the mean CV of each longitudinal contraction was estimated. During a period of 5 minutes,  
283 the mean of amplitude and frequency of spontaneous contractions were analysed. ACh-induced motor  
284 responses were measured as the area under the curve (AUC) during the first 3 min of ACh response and  
285 expressed as a percentage of control (3 min of the AUC area before addition of ACh). The AUC was  
286 normalized by the wet weight of each preparation. Results were expressed as a percentage of control group  
287 values (100%).

288 Each experimental protocol was systematically made on one segment of ileum per mouse and was repeated  
289 on 4-10 animals.

#### 290 **2.6.6. Histopathological study**

291 Pieces of proximal and distal colon were fixed in 10% buffered formalin (Panreac, Barcelona, Spain), then  
292 dehydrated, embedded in paraffin blocks, and cut into 4  $\mu$ m-thick sections. They were stained with  
293 haematoxylin-eosin (HE). The analysis of these samples was performed by a pathologist by measuring the  
294 thickness of the intestinal mucosa in 5 different areas using a Nikon Eclipse Ci microscope, a Nikon DS-  
295 Ri 1 digital still camera, and a Nikon NIS calibrated digital image analysis system. Histopathological  
296 analysis focused on normality or alteration of architecture and relative proportions of the structures,  
297 presence of abnormal vascularization, assessment of degenerative or necrotic features, degree of  
298 inflammation (cell infiltrates), and abnormal growth (atrophy, hyperplasia, hypertrophy and neoplasia).

#### 299 **2.6.7. Determination of MPO activity**

300 Samples of distal colon stored at -80  $^{\circ}$ C were homogenized in 0.1 M phosphate buffer (pH 7.4) and then  
301 centrifuged at 15.000 rpm at 4  $^{\circ}$ C for 10 min, the supernatant fraction was used for the measurements of  
302 MPO content by the MPO activity Assay Kit (Sigma Aldrich). MPO activity was expressed as U/mg  
303 protein.

#### 304 **2.6.8. Determination of IL-6 and IL-10**

305 Levels of IL-6 and IL-10, pro- and anti-inflammatory interleukins, respectively, were measured in colon  
306 homogenates (1:5 dilution) and samples of cells (1:2 dilution) using ELISA kits (KIT Ready-Set-Go!,  
307 eBioscience) as per the manufacturer's instructions.

#### 308 **2.6.9. Protein extraction and Western blot analysis for determination of iNOS and COX-2**

309 Samples of distal colon were homogenized in cold lysis buffer containing 150 mM NaCl, 10 mM Tris pH  
310 7.5 and 1% Triton X-100 supplemented with a complete EDTA-free protease inhibitor cocktail (Roche).  
311 The homogenates were centrifuged at 15.000 rpm at 4  $^{\circ}$ C for 20 min, and the protein concentration of the  
312 supernatants was assessed using a Pierce BCA Protein Assay Kit (Thermo-Fisher).

313 Proteins were separated on 7.5% SDS-PAGE gels (Bio-Rad) and transferred onto PVDF membranes  
314 (Immobilon-P; Millipore). The membranes were blocked with 5% non-fat milk in Tris buffered saline  
315 supplemented with 0.1% Tween-20 (TBST) at room temperature during 2h. After that, membranes were  
316 incubated with primary antibodies for iNOS (1:200, BD Biosciences), COX-2 (1:1000, BD Biosciences)  
317 and  $\beta$ -actin (1:5000, Santa Cruz Biotechnology, as loading control) overnight in TBST with 1% non-fat  
318 milk at 4  $^{\circ}$ C. Membranes were then washed and incubated with peroxidase-conjugated secondary antibodies  
319 in TBST with 1% non-fat milk for 2h at room temperature. The immunocomplexes were detected by a



320 chemiluminescent reaction using a Western Bright Sirius (Advansta) kit and the signal was visualized in  
321 VersaDoc (Bio-Rad). Results were expressed as iNOS/actin or COX-2/actin ratios in arbitrary  
322 densitometric units.

### 323 **2.6.10. Immunofluorescence and confocal microscopy**

324 Proximal colon sections were deparaffinised through Histo-Clear (National Diagnostics), and rehydrated in  
325 decreasing concentrations of ethanol and rinsed with distilled water and Tris buffered saline (TBS; 65 mM  
326 Tris-Cl, pH 7.5; 150 mM NaCl). Tissues were treated for 30 minutes with sodium borohydride (NaBH<sub>4</sub>;  
327 1% w/v) in ice-cold TBS to reduce auto-fluorescence. Non-specific binding was blocked with 1% BSA and  
328 0.5% Triton X100 in TBS (blocking buffer) for 3x10 minutes. Then, slices were incubated at 4 °C overnight  
329 with a goat anti-ZO-1 antibody (1:50, Santa Cruz Biotechnology). The next day, sections were washed with  
330 blocking buffer (3x10 minutes) and incubated with a donkey anti-goat IgG-AlexaFluor 488 secondary  
331 antibody (1:2000, Molecular Probes) in darkness for 2 h at room temperature. After 3 washes for 15 minutes  
332 each in TBS, preparations were mounted with Fluoromount-G (SouthernBiotech) containing 0.1% DAPI  
333 (Life Biotechnologies) and 0.4% DraQ5 (BioStatus) for DNA staining, and visualized under a confocal  
334 microscope (Olympus FV10). The images were acquired using the Olympus FV10-ASW 3.0 viewer  
335 software and further processed with ImageJ.

### 336 **2.7. Statistical analysis**

337 Data are expressed as mean ± SEM, and differences between groups were statistically analysed using the  
338 GraphPad Prism Software v6. One-way analysis of variance (ANOVA) followed by Tukey's (when  
339 parametric distribution is observed), Kruskal Wallis tests (non parametric) or unpaired t-tests were used to  
340 detect differences. Parameters of spontaneous contractions (amplitude and frequency) were analysed as  
341 previously described on duodenum segments (Fagundes et al. 2007). Significance level was set to  $p < 0.05$ .

342

## 343 **3. Results**

### 344 **3.1. Phytochemical analysis**

#### 345 **3.1.1. Phenolic compounds**

346 The HPLC-DAD analysis of the extract revealed the presence of fifteen phenolic compounds, including ten  
347 phenolic acids (**1-9, 12**) and five flavonols (**10, 11, 13, 14** and **15**) (Figure 1a). The ethanolic extract herein  
348 studied showed a high content of phenolic compounds (134.4 mg/g of dry extract) (Table 1). Representing  
349 more than 70% of all phenolics quantified, the hydroxycinnamic acids derived from caffeoylquinic acid  
350 were the dominant compounds in the extract, the pair 3,4-di-*O*-caffeoylquinic and 3,5-di-*O*-caffeoylquinic  
351 acids (**7+8**) being dominant (40.95 mg/g of dry extract), followed by 1,5-di-*O*-caffeoylquinic (**9**) and 4,5-  
352 di-*O*-caffeoylquinic (**12**) acids (24.73 and 23.14 mg/g of dry extract, respectively) (Table 1). The flavonol  
353 quercetin-3-*O*-galactoside (**10**) was the fourth most representative compound in the extract (15.16 mg/g of  
354 dry extract) and the most abundant flavonoid found.

#### 355 **3.1.2. Pigments**

356 The analytical methodology employed allowed the determination, for the first time, of two carotenoids,  
357 comprising one xanthophyll, lutein (**17**), and β-carotene (**23**), as well as of chlorophyll *b* (**6**), the chlorophyll  
358 *a* demetalation derivative pheophytin *a* (**22**), and compounds with chlorophyll *a*-like UV-vis spectrum,  
359 labelled as chlorophyll *a* derivatives (**20** and **21**). Two other compounds (compounds **18** and **19**) were also

360 found; although their identity is not known, their chromatographic behaviour and UV-vis spectra allow  
361 classifying them as xanthophylls (Figure 1b). Among the carotenoids and chlorophylls quantified in our  
362 study, lutein (**17**) was the most representative, being its content higher than 55% of total pigments (Table  
363 1).

### 364 **3.2. Antioxidant potential in cell-free assays**

365 RT extract showed an effective and dose-dependent antioxidant effect against  $O_2^{\cdot -}$  radicals generated by  
366 X/XO system, presenting an  $IC_{50}$  of 36.7  $\mu\text{g/mL}$ . An  $IC_{50}$  value of 0.46  $\mu\text{g/mL}$  was obtained for gallic acid,  
367 the positive control tested under the same conditions (Figure 2a).

368 Moreover, RT extract, at higher doses, was also able to inhibit the xanthine oxidase enzyme responsible for  
369 this reaction, with an  $IC_{50}$  value of 929.86  $\mu\text{g/mL}$  (Figure 2b).

370 The capacity of the RT extract to scavenge superoxide radical generated by a non-enzymatic system was  
371 confirmed when this radical was generated by a chemical system, which indicated an  $IC_{50}$  of 47.0  $\mu\text{g/mL}$   
372 (Figure 2c). An  $IC_{50}$  value of  $10.97 \pm 0.68$   $\mu\text{g/mL}$  was obtained with quercetin, the positive control tested  
373 under the same conditions. This fact allows to conclude that the superoxide scavenging properties are  
374 independent to xanthine-oxidase inhibition.

### 375 **3.3. Anti-inflammatory activity**

376 RT extract also inhibited 5-LOX, showing an  $IC_{50}$  of 74.0  $\mu\text{g/mL}$  (Figure 2d). An  $IC_{50}$  value of  $3.29 \pm 0.21$   
377  $\mu\text{g/mL}$  was obtained for quercetin, the positive control tested under the same conditions.

378 LPS (1  $\mu\text{g/mL}$ ) increased the nitrite production and TNF- $\alpha$  expression in murine macrophages compared  
379 with control. RT extract presented a significant capacity to reduce to basal levels both NO production as  
380 well as the expression of the pro-inflammatory cytokine TNF- $\alpha$  in LPS-stimulated J774.2 macrophages  
381 (Figure 2e and 2f). These results confirmed the anti-inflammatory potential of RT extract.

### 382 **3.4. Protective effects of the RT extract on the development and recovery of DSS-induced colitis.**

383 RT *per se* did not affect clinical state of animals, as shown in Figure 3b. Colitis was manifested by weight  
384 loss, presence of blood in faeces, and changes in stool consistency. The DAI scores in Figure 3b showed  
385 that the RT extract, to different doses, delayed the appearance of colitis symptoms. However, at longer  
386 DSS-exposure ( $\geq 4$  days), this protective effect vanished. Yet, the RT extract improved symptoms during  
387 the recovery phase of the animals. Thus, total disease severity was found to be lower in mice treated with  
388 RT extract vs. untreated colitic animals. SSZ, used as standard treatment of UC, was also effective in the  
389 initial phase, although less than RT (Figure 3b and 3c). In contrast to RT, SSZ did not improve disease  
390 severity in the recovery period (day 20) (Figure 3c).

### 391 **3.5. RT extract attenuates macroscopic colon damage in DSS-induced acute colitis.**

392 DSS administration reduced colonic length in all groups (Figure 4a). Administration of RT<sub>50</sub> extract but not  
393 the reference drug SSZ significantly attenuated this effect. Also, wall thickness was increased in both  
394 proximal and distal colon after DSS. RT, dose-dependently, and SSZ mitigated this effect (Figure 4c and  
395 4d), although only reached statistical significance the effect of SSZ in proximal colon. Finally, DSS-  
396 induced macroscopic damage, as seen in Figure 4b, was partially reversed by the RT extracts and SSZ. The  
397 administration of RT extract in animals that were not challenged with DSS did not produce any pathological  
398 alterations suggesting that the RT is not toxic at the dosage used here (Figure 4a-d).

### 399 **3.6. Functional studies of ileal contractility**

400 Figure 5a shows the typical spontaneous contractile activity of longitudinal muscle segments of ileum  
401 isolated from different groups (control, RT<sub>50</sub>, water+DSS, RT<sub>5</sub>+DSS, RT<sub>25</sub>+DSS, and RT<sub>50</sub>+DSS group).  
402 RT<sub>50</sub> extract *per se* did not change motility pattern. As expected, DSS severely impaired spontaneous  
403 contractions. Thus, as shown in Figure 5b, the longitudinal smooth muscle contractions were highly  
404 irregular and intermittent over time. In contrast, spontaneous contractions of the ileum segments from the  
405 RT-treated animals showed dose-dependent improvement of rhythm, being very similar to control with the  
406 higher doses of the plant (p=0.0095 water+DSS vs. RT<sub>25</sub>+DSS and p=0.0061 water+DSS vs. RT<sub>50</sub>+, in a  
407 Mann-Whitney test). Figure 5c shows that the DSS treatment also significantly decreased the amplitude of  
408 spontaneous contractions if compared to control, except for RT<sub>50</sub>+DSS-treated animals (p=0.0016  
409 water+DSS vs. RT<sub>50</sub>+DSS, Mann-Whitney test). The DSS treatment mildly reduced the frequency of ileal  
410 spontaneous contractions but the difference did not reach statistical significance (Figure 5d).  
411 The DSS treatment significantly decreased the contractions to ACh. Again, RT extract at higher but not  
412 lower doses prevented this effect (Figure 5e). Taken together, these results show that the RT treatment, in  
413 a dose dependent way, was able to ameliorate DSS effects on ileal motility and contractile capacity.  
414 The highest dose of RT was chosen for the rest of experiments due to its better effects on the clinical  
415 symptomatology, tissue damage, and functional studies.

### 416 **3.7. RT extract ameliorates histopathological alterations in DSS-induced colitis.**

417 Colon sections of DSS-treated animals showed severe colitis with massive destruction of the intestinal  
418 mucosa and severe infiltration of inflammatory cells into the lamina propria, especially in the distal colon  
419 (Figure 4f). In contrast, DSS-induced damage and inflammation was significantly lower in the distal colon  
420 in RT<sub>50</sub>-treated animals (Figure 4g), while the damage in the proximal colon was similar. The controls and  
421 the RT<sub>50</sub>-treated animals showed a typical colon structure, with normal sized intestinal villi, a normal lamina  
422 propria and submucosa with mild cell infiltrates (Figure 4e and 4h).

### 423 **3.8. Biochemical markers of inflammation (MPO, IL-6, IL-10, iNOS, COX-2) in colonic tissue**

424 MPO activity and IL-6 levels were significantly higher in colonic tissues of the DSS group than in controls.  
425 RT<sub>50</sub> extract significantly reduced the DSS effect (Figure 6a and 6b). Colon of animals treated with DSS  
426 showed a decrease in the levels of IL-10 respect to controls (p = 0.057), an effect that was not prevented by  
427 the treatment with RT<sub>50</sub> extract (Figure 6c).

428 The effect of RT on inflammation was also studied by assessing the protein expression of iNOS and COX-  
429 2. As shown in Figure 6d and 6e, as expected, the expression levels of iNOS and COX-2 were significantly  
430 increased in colonic tissues of DSS group respect to control. RT<sub>50</sub> extract did not induce *per se* expression  
431 of COX-2 or iNOS but it significantly prevented the induction of these enzymes by DSS.

### 432 **3.9. RT extract prevents DSS-induced loss of ZO-1.**

433 ZO-1, a tight junction protein of the intestinal epithelial barrier, was visualized by immunofluorescence /  
434 confocal microscopy in colon samples of control, water+DSS and RT<sub>50</sub>+DSS groups.

435 As shown in Figure 6a, ZO-1 was mainly expressed at the apical border of the lining epithelium in control  
436 animals. Furthermore, a dotted-spherical pattern of expression, likely cytoplasmic, was also observed  
437 deeper in the tissue (Figure 7a). In contrast, in 3 out of 3 DSS mice apical ZO-1 expression was lost, while  
438 the dotted-spherical expression was preserved (Figure 7b). The treatment with RT<sub>50</sub> extract prevented the  
439 loss of apical ZO-1 in the lining epithelium of DSS-challenged animals in 3 out of 3 animals (Figure 7c).

440

#### 441 **4. Discussion**

442 This study characterized phytochemically an ethanolic extract of RT and investigated its ability to improve  
443 experimental DSS-induced colitis in mice by using a wide range of cell-free, cell-based, *in-vivo* and *ex-vivo*  
444 techniques. Data demonstrate that RT was capable of ameliorating clinical symptoms of colitis in this  
445 model, i.e., weight loss, loose and bloody stool, inflammation, damage of the colon mucosa, including the  
446 preservation of the intestinal barrier. Moreover, the extract has been shown to normalize the severely  
447 impaired ileal contractility observed in this model. Anti-inflammatory and antioxidant effects have also  
448 been detected, which could explain the observed *in-vivo* benefits. It is the first time that a study provides  
449 experimental proof for the utility of *Jasonia glutinosa* as herbal medicine or herbal supplement in UC.

450

451 RT extract is rich in polyphenols that are well-known antioxidant agents. Some of them have been described  
452 to possess *in-vitro* anti-inflammatory activities (Hussain et al. 2016). A recent study simulating an *in vitro*  
453 digestion showed that digestive processes may alter the composition of *Jasonia glutinosa* extracts (Ortega-  
454 Vidal et al. 2019); however, our extract preserved its anti-inflammatory properties both in *in vitro* and *in*  
455 *vivo* assays.

456 RT extract showed a rich and varied phenolic profile, composed of flavonols and hydroxycinnamic acids,  
457 predominantly caffeoylquinic acids (Figure 1a, Table 1). Previous phytochemical studies have shown the  
458 presence of flavonoids, like quercetin, kaempferol derivatives and phenolic acids in methanolic and  
459 aqueous extract of RT (Ortega-Vidal et al. 2019; Rubio et al. 1995; Valero et al. 2013). We here show that  
460 ethanolic extract is also rich in phenolic acids, in particular caffeoylquinic acids, and pigments, which could  
461 be of interests for industrial purposes as ethanol (instead of methanol as solvent) is permitted and used in  
462 pharmaceutical products. Other studies have found kaempferol in RT extracts, as well as some glycosides  
463 of quercetin, such as quercetin-3-*O*-rhamnoside, quercetin-3-*O*-rutinoside. Oral administration of high  
464 amounts of isolated flavonoids also showed beneficial effects on DSS-induced colitis in mice as they  
465 prevented weight loss, histological alterations and inflammation caused by colitis (Brückner et al. 2012;  
466 Camuesco et al. 2004; Comalada et al. 2005; Park et al. 2012). Probably, these actions could be mediated  
467 through down-regulation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), that  
468 results in a reduction of pro-inflammatory cytokines as IL-6, IL-1β and TNF-α, iNOS expression and NO  
469 levels, LOX and COX-2 expression, prostaglandin E<sub>2</sub> levels and MPO activity (Brückner et al. 2012;  
470 Camuesco et al. 2004; Comalada et al. 2005; Liu et al. 2014; Park et al. 2012).

471 Concerning caffeoylquinic acids found in our RT extract, it is worth mentioning that esters formed by  
472 caffeic and quinic acids (caffeoylquinic acids), represent an abundant group of plant polyphenols present  
473 in human diet and their role in controlling oxidative and inflammatory stress conditions is reviewed in  
474 previous works (Liang and Kitts 2015). The anti-ulcerogenic properties of some caffeoylquinic acids, such  
475 as 5-*O*-caffeoylquinic, 3,4-di-*O*-caffeoylquinic and 3,5-di-*O*-caffeoylquinic acids has already been  
476 documented (Lee et al. 2010). In several animal studies, the oral administration of 5-*O*-caffeoylquinic acid  
477 showed protective effects in different induced-colitis models, by reducing neutrophil infiltration and  
478 inhibition of the NF-κB pathway (Liang and Kitts 2015) and by promoting growth of *Akkermansia* in mice  
479 (Zhang et al. 2017).

480  
481 Carotenoids represent the most abundant lipid-soluble phytochemicals, and *in-vitro* and *in-vivo* studies have  
482 suggested their antioxidant and anti-inflammatory properties (Kaulmann and Bohn 2014). The problems  
483 observed in the digestion and absorption of fat-soluble compounds in patients with IBD could delay their  
484 protective effects, as they are described against colon related diseases, such as cancer, Crohn disease and  
485 UC (Slattery et al. 2000).  
486  
487 Two biologically important carotenoids were found in our RT extract, lutein (**17**) and  $\beta$ -carotene (**23**).  
488 Głabska and colleagues reported that a higher intake of a mixture of lutein and zeaxanthin (ca. 1800  $\mu\text{g}$ )  
489 was associated with the reduction of faecal blood, mucus and pus in individuals with UC (Głabska et al.  
490 2016), and with lower incidence of constipation in individuals with UC in remission phase (Głabska et al.  
491 2019). Likewise,  $\beta$ -carotene (at doses of 5-50  $\mu\text{M}$ ) was described to ameliorate UC-associated local and  
492 systemic damage in mice, by acting on multiple targets (Kaulmann and Bohn 2014; Trivedi and Jena 2015).  
493 RT extract presented a lutein content (ca. 148  $\mu\text{g/g}$ ) almost eight times higher than that of  $\beta$ -carotene (ca.  
494 20  $\mu\text{g/g}$ ) (Table 1). Although in the work herein a daily content of 50 mg RT of extract/kg bw was  
495 administrated to the animals and, at this doses, the concentration of lutein and  $\beta$ -carotene (ca. 7.4  $\mu\text{g}$  and 1  
496 ng, respectively) were much lower than those showing therapeutic efficacy (Głabska et al. 2019; Głabska  
497 et al. 2016; Kaulmann and Bohn 2014; Trivedi and Jena 2015), the possibility of contribution of these  
498 compounds as themselves, as well as of the synergic effects between them, cannot be ignored.  
499  
500 Concerning the underlying mechanisms by which RT shows therapeutic efficacy in DSS-induced colitis,  
501 our *in-vitro* studies revealed that RT extract strongly scavenged superoxide radicals using the X/XO system.  
502 However, when using this assay, we cannot fully exclude a direct inhibitory effect on the enzyme itself.  
503 Indeed, we found that the extract presented a low XO inhibitory activity ( $\text{IC}_{50} = 929.86 \mu\text{g/mL}$ ). Still, when  
504 the extract was tested in the NADH/PMS system, we found a clear-cut  $\text{O}_2^{\cdot-}$  scavenging effect.  
505 Respecting the anti-inflammatory properties of RT in the DSS model, we found that RT inhibited 5-LOX-  
506 activity, which is known to be required for the synthesis of pro-inflammatory molecules, i.e. leukotrienes.  
507 Among several isoforms, 5-LOX is one of the most important in physiological and pathological processes  
508 (Rådmark et al. 2015) and LOX-inhibitors have been found in plant extracts (Schneider and Bucar 2005).  
509 Therefore, the lower degree of inflammation in RT-treated mice can be explained through 5-LOX inhibiting  
510 properties. In addition, RT extract reduced the production of NO and TNF- $\alpha$  induced by LPS in J774.2  
511 macrophages. In colonic tissue, RT extract decreased MPO activity, the rise in IL-6 levels as well as in  
512 COX-2 and iNOS expression. On the other hand, RT extract had no effect on IL-10 levels. Together, these  
513 findings suggest that RT has potent and multifaceted anti-inflammatory properties involving several signal  
514 pathways and cell systems. Interestingly, this anti-inflammatory profile shares similarities with anti-  
515 inflammatory properties of other medicinal plant compounds, such as corilagin, a TGF $\beta$ 1-inhibiting  
516 molecule (Xiao et al. 2013).  
517  
518 Our immune histological studies suggest that the efficacy of this extract also relied on maintaining the  
519 integrity of intestinal barrier intact, as concluded from the conserved ZO-1 expression at enterocytes tight

520 junctions. Intact functioning of tight junctions is essential for building the intestinal barrier (Mankertz and  
521 Schulzke 2007; Poritz et al. 2007). In addition, it is well known that cytokines regulate tight junctions  
522 (Capaldo and Nusrat 2009) and, particularly, TNF $\alpha$  and IL-6 have been reported to impair intestinal barrier  
523 by interfering with ZO-1 protein expression and localization (Desai et al. 2002; Ma et al. 2004). The  
524 protective effect of RT on the intestinal barrier may therefore be explained by RT's ability to prevent TNF $\alpha$   
525 and IL-6 induction.

526

527 Regarding appearance and progressive aggravation of clinical symptoms, RT was also effective. However,  
528 this therapeutic effect was seen during the first three days of the DSS treatment but not during the next four  
529 days. Additionally, RT significantly promoted recovery after cessation of the inflammatory stimulus. If  
530 compared this efficacy with that of a standard anti-inflammatory treatment for UC, i.e. SSZ, RT showed  
531 similar or even better efficacy considering that RT but not SSZ delayed the development of severe  
532 symptomatology and promoted recovery. At the anatomical/histological level, RT extract prevented to a  
533 considerable extent the reduction of colonic length and the increase in the wall thickness that are typical  
534 features of this DSS model. It is worth mentioning that studies testing green tea polyphenols (Oz et al.  
535 2013) or foods rich in polyphenols (Kang et al. 2017; Kim et al. 2014; Singh et al. 2009) and also using  
536 SSZ as standard treatment in this colitis model, showed comparable therapeutic efficacy.

537

538 Besides morphological and histological changes, it is known that DSS impairs motility in the colon and,  
539 more recently, also in the small intestine (Lykov et al. 2018; Yazbeck et al. 2011). Here, we provide  
540 additional evidence for this harmful impact of DSS on ileal contractility by showing un-coordinated and  
541 weaker spontaneous contractions and weaker ACh-induced responses. Importantly, we show that RT, in a  
542 dose dependent manner, was also capable of preventing this alteration. Thus, RT<sub>50</sub>-treated mice exhibited  
543 coordinated rhythmic spontaneous motility and conserved amplitude of contractions. This findings are also  
544 in line with our previous work showing that RT at 50 mg/kg normalized whole gastrointestinal transit in  
545 this model of colitis (Castro et al. 2016). This protective effect of RT on ileal motor function may be due  
546 to a decrease on local inflammatory mediators as shown with other vegetal extracts (Chaudhuri et al. 2000).  
547 This beneficial effect on intestinal motility is likely the functional outcome of RT's complex anti-  
548 inflammatory, antioxidant and tissue-protective effects.

549

## 550 **5. Conclusions**

551 In summary, this work provides evidence that RT extract has beneficial effects in a DSS-induced colitis  
552 model, improving clinical symptoms, attenuating tissue damage, preserving the intestinal barrier and  
553 normalizing the intestinal contractility. The benefits of RT extract could be related to its biologically-  
554 relevant chemical composition. We suggest that RT may be of potential therapeutic utility in UC and other  
555 inflammatory bowel diseases.

556

## 557 **Declarations**

558 **Ethics approval and consent to participate:** This study was performed in accordance with the European  
559 Union Directive 2010/63 EU concerning experimental animal protection. Experimental protocols were  
560 approved by the Ethics Committee of Universidad de Zaragoza.

561 **Consent for publication:** All authors gave their informed consent prior to their inclusion in the study.

562 **Conflict of interest:** The authors declare that they have no conflict of interest.

563 **Acknowledgements:** This work was supported by the government of Aragón, Spain (E-02 and B61),  
564 Fundación Ibercaja-Universidad de Zaragoza (ref. JIUZ-2018-BIO-09 and BIO-2015-02), National Funds  
565 (FCT/MEC, Fundação para a Ciência e a Tecnologia/Ministério da Educação e Ciência) through project  
566 UID/QUI/50006/2013, co-financed by European Union (FEDER under the Partnership Agreement  
567 PT2020), from Norte Portugal Regional Operational Programme (NORTE 2020), under the PORTUGAL  
568 2020 Partnership Agreement, through the European Regional Development Fund (ERDF) (project  
569 NORTE-01-0145-FEDER-000024), and from Programa de Cooperación Interreg V-A España – Portugal  
570 (POCTEP) 2014-2020 (project 0377\_IBERPHENOL\_6\_E) and the European Social Fund “Construyendo  
571 Europa desde Aragón”. The authors also thank the Scientific Services of the Centre for Biomedical  
572 Investigation (CIBA) for technical assistance. Jose Manuel López Cano is acknowledged for carrying out  
573 *in vitro* experiments with macrophages and Dr. Elisa Langa (USJ) for extraction procedures with the plant  
574 material.

575

576 **References**

- 577 Akerreta S, Cavero RY, López V, Calvo MI (2007) Analyzing factors that influence the folk use and  
578 phytonomy of 18 medicinal plants in Navarra. *J Ethnobiol Ethnomed* 3:16.  
579 <https://doi.org/10.1186/1746-4269-3-16>
- 580 Alarcón R, Pardo-de-Santayana M, Priestley C, Morales R, Heinrich M (2015) Medicinal and local food  
581 plants in the south of Alava (Basque Country, Spain). *J. Ethnopharmacol* 176:207–224.  
582 <https://doi.org/10.1016/j.jep.2015.10.022>
- 583 Amaro H et al (2015) Effect of solvent system on extractability of lipidic components of *Scenedesmus*  
584 *obliquus* (M2-1) and *Gloeotheca* sp. on antioxidant scavenging capacity thereof. *Mar. Drugs*  
585 13(10):6453–6471. <https://doi.org/10.3390/md13106453>
- 586 Barbosa M et al (2017) Phlorotannin extracts from Fucales: Marine polyphenols as bioregulators engaged  
587 in inflammation-related mediators and enzymes. *Algal Res* 28:1–8.  
588 <https://doi.org/10.1016/J.ALGAL.2017.09.009>
- 589 Baumgart DC, Carding SR (2007) Inflammatory bowel disease: cause and immunobiology. *Lancet*  
590 369(9573):1627–1640. [https://doi.org/10.1016/S0140-6736\(07\)60750-8](https://doi.org/10.1016/S0140-6736(07)60750-8)
- 591 Baumgart DC, Sandborn WJ (2007) Inflammatory bowel disease: clinical aspects and established and  
592 evolving therapies. *Lancet* 369(9573):1641–1657. [https://doi.org/10.1016/S0140-6736\(07\)60751-X](https://doi.org/10.1016/S0140-6736(07)60751-X)
- 593 Bermejo BP, Abad MJ, Díaz AM, Villaescusa L, González MA, Silván AM (2002) Sesquiterpenes from  
594 *Jasonia glutinosa*: in vitro anti-inflammatory activity. *Biol. Pharm. Bull* 25(1):1–4.
- 595 Brückner M, Westphal S, Domschke W, Kucharzik T, Lügering A (2012) Green tea polyphenol  
596 epigallocatechin-3-gallate shows therapeutic antioxidative effects in a murine model of colitis. *J.*  
597 *Crohn's Colitis* 6(2):226–235. <https://doi.org/10.1016/j.crohns.2011.08.012>
- 598 Camuesco D et al (2004) The intestinal anti-inflammatory effect of quercitrin is associated with an  
599 inhibition in iNOS expression. *Br. J. Pharmacol* 143(7):908–918.  
600 <https://doi.org/10.1038/sj.bjp.0705941>
- 601 Capaldo CT, Nusrat A (2009) Cytokine regulation of tight junctions. *Biochim. Biophys. Acta* 1788(4):864–  
602 871. <https://doi.org/10.1016/j.bbamem.2008.08.027>
- 603 Castro M et al (2016) Spasmolytic effect of *Jasonia glutinosa* on rodent intestine. *Rev esp enferm dig*  
604 108:785–789. <https://doi.org/10.17235/reed.2016.4327/2016>
- 605 Chaudhuri L et al (2000) Prokinetic effect of black tea on gastrointestinal motility. *Life Sci* 66(9):847–854.
- 606 Comalada M et al (2005) In vivo quercitrin anti-inflammatory effect involves release of quercetin, which  
607 inhibits inflammation through down-regulation of the NF- $\kappa$ B pathway. *Eur. J. Immunol* 35(2):584–592.  
608 <https://doi.org/10.1002/eji.200425778>
- 609 Dai Y et al (2017) Jianpi Qingchang decoction regulates intestinal motility of dextran sulfate sodium-  
610 induced colitis through reducing autophagy of interstitial cells of Cajal. *World J Gastroenterol*  
611 23(26):4724–4734. <https://doi.org/10.3748/wjg.v23.i26.4724>
- 612 Danese S, Fiocchi C (2011) Ulcerative colitis. *N. Engl. J. Med* 365(18):1713–1725.  
613 <https://doi.org/10.1056/NEJMra1102942>
- 614 Desai TR, Leeper NJ, Hynes KL, Gewertz BL (2002) Interleukin-6 causes endothelial barrier dysfunction  
615 via the protein kinase C pathway. *J. Surg. Res* 104(2):118–123. <https://doi.org/10.1006/jsre.2002.6415>



616 Fagundes DS, Grasa L, Arruebo MP, Plaza MA, Murillo MD (2007) Ca<sup>2+</sup>-activated K<sup>+</sup> channels involved  
617 in duodenal dismotility induced by ethanol. *Alcohol Alcohol* 42(4):291–295.  
618 <https://doi.org/10.1093/alcalc/aggm037>

619 Głąbska D, Guzek D, Zakrzewska P, Lech G (2019) Intake of Lutein and Zeaxanthin as a Possible Factor  
620 Influencing Gastrointestinal Symptoms in Caucasian Individuals with Ulcerative Colitis in Remission  
621 Phase. *J. Clin. Med* 8(1):77 <https://doi.org/10.3390/jcm8010077>

622 Głąbska D, Guzek D, Zakrzewska P, Włodarek D, Lech G (2016) Lycopene, Lutein and Zeaxanthin may  
623 reduce faecal blood, mucus and pus but not abdominal pain in individuals with ulcerative colitis.  
624 *Nutrients* 8(10):613. <https://doi.org/10.3390/nu8100613>

625 Hussain T, Tan B, Yin Y, Blachier F, Tossou MCB, Rahu N (2016) Oxidative stress and inflammation:  
626 What polyphenols can do for us? *Oxid Med Cell Longev* 2016:7432797.  
627 <https://doi.org/10.1155/2016/7432797>

628 Kang S et al (2017) Aronia berry extract ameliorates the severity of dextran sodium sulfate-induced  
629 ulcerative colitis in mice. *J. Med. Food* 20(7):667–675. <https://doi.org/10.1089/jmf.2016.3822>

630 Kaulmann A, Bohn T (2014) Carotenoids, inflammation, and oxidative stress—implications of cellular  
631 signaling pathways and relation to chronic disease prevention. *Nutr. Res* 34(11):907–929.  
632 <https://doi.org/10.1016/j.nutres.2014.07.010>

633 Kim K et al (2014) Sasa quelpaertensis leaf extract suppresses dextran sulfate sodium–induced colitis in  
634 mice by inhibiting the proinflammatory mediators and mitogen-activated protein kinase  
635 phosphorylation. *Nutr. Res* 34(10):894–905. <https://doi.org/10.1016/j.nutres.2014.09.002>

636 Lee B et al (2010) Anti-ulcerogenic effect and HPLC analysis of the caffeoylquinic acid-rich extract from  
637 *Ligularia stenocephala*. *Biol. Pharm. Bull* 33(3):493–497.

638 Liang N, Kitts D (2015) Role of chlorogenic acids in controlling oxidative and inflammatory stress  
639 conditions. *Nutrients* 8(1):16. <https://doi.org/10.3390/nu8010016>

640 Liu S et al (2014) Lotus Leaf (*Nelumbo nucifera*) and its active constituents prevent inflammatory  
641 Responses in macrophages via JNK/NF- $\kappa$ B signaling pathway. *Am. J. Chin. Med* 42(4):869–889.  
642 <https://doi.org/10.1142/S0192415X14500554>

643 López V, Akerreta S, Casanova E, García-Mina J, Cavero R, Calvo M (2008) Screening of spanish  
644 medicinal plants for antioxidant and antifungal activities. *Pharm. Biol* 46(9):602–609.  
645 <https://doi.org/10.1080/13880200802179634>

646 Low D, Nguyen D, Mizoguchi E (2013) Animal models of ulcerative colitis and their application in drug  
647 research. *Drug Des. Devel. Ther* 7:1341. <https://doi.org/10.2147/DDDT.S40107>

648 Lykov AP, Poveshchenko O V., Bondarenko NA, Surovtseva MA, Kim II, Bgatova NP (2018) Therapeutic  
649 potential of biomedical cell product in DSS-induced inflammation in the small intestine of C57Bl/6J  
650 mice. *Bull. Exp. Biol. Med* 165(4):576–580. <https://doi.org/10.1007/s10517-018-4216-5>

651 Ma T et al (2004) TNF- $\alpha$ -induced increase in intestinal epithelial tight junction permeability requires NF-  
652  $\kappa$ B activation. *Am. J. Physiol. Liver Physiol* 286(3):G367–376.  
653 <https://doi.org/10.1152/ajpgi.00173.2003>

654 Mankertz J, Schulzke JD (2007) Altered permeability in inflammatory bowel disease: pathophysiology and  
655 clinical implications. *Curr. Opin. Gastroenterol* 23(4):379–383.

656 <https://doi.org/10.1097/MOG.0b013e32816aa392>

657 Molodecky N et al (2012) Increasing incidence and prevalence of the inflammatory bowel diseases with  
658 time, based on systematic review. *Gastroenterology* 142(1):46–54.e42, quiz e30.  
659 <https://doi.org/10.1053/j.gastro.2011.10.001>

660 Ortega-Vidal J, Ruiz-Riaguas A, Fernández-de Córdova ML, Ortega-Barrales P, Llorent-Martínez EJ  
661 (2019) Phenolic profile and antioxidant activity of *Jasonia glutinosa* herbal tea. Influence of simulated  
662 gastrointestinal in vitro digestion. *Food Chem* 287:258–264.  
663 <https://doi.org/10.1016/j.foodchem.2019.02.101>

664 Oz H, Chen T, de Villiers W (2013) Green tea polyphenols and sulfasalazine have parallel anti-  
665 inflammatory properties in colitis models. *Front. Immunol* 4:132.  
666 <https://doi.org/10.3389/fimmu.2013.00132>

667 Pardo Santayana M, Morales R (2004) Consideraciones sobre el género *Jasonia* (Compositae, Inuleae).  
668 Sistemática y usos. *Acta Bot. Malacit.*

669 Park M, Ji G, Sung M (2012) Dietary kaempferol suppresses inflammation of dextran sulfate sodium-  
670 induced colitis in mice. *Dig. Dis. Sci* 57(2):355–363. <https://doi.org/10.1007/s10620-011-1883-8>

671 Poritz L, Garver K, Green C, Fitzpatrick L, Ruggiero F, Koltun W (2007) Loss of the tight junction protein  
672 ZO-1 in dextran sulfate sodium induced colitis. *J. Surg. Res* 140(1):12–19.  
673 <https://doi.org/10.1016/j.jss.2006.07.050>

674 Rådmark O, Werz O, Steinhilber D, Samuelsson B (2015) 5-Lipoxygenase, a key enzyme for leukotriene  
675 biosynthesis in health and disease. *Biochim. Biophys. Acta* 1851(4):331–339.  
676 <https://doi.org/10.1016/j.bbali.2014.08.012>

677 Rodríguez-Chávez J, Coballase-Urrutia E, Nieto-Camacho A, Delgado-Lamas G (2015) Antioxidant  
678 capacity of “Mexican Arnica” *heterotheca inuloides* cass natural products and some derivatives: their  
679 anti-inflammatory evaluation and effect on *C. elegans* life span. *Oxid. Med. Cell. Longev* 2015:843237.  
680 <https://doi.org/10.1155/2015/843237>

681 Rubio B, Villaescusa L, Diaz A, Fernandez L, Martin T (1995) Flavonol Glycosides from *Scolymus*  
682 *hispanicus* and *Jasonia glutinosa*. *Planta Med* 61(6):583. <https://doi.org/10.1055/s-2006-959386>

683 Schneider I, Bucar F (2005) Lipoxygenase inhibitors from natural plant sources. Part 2: medicinal plants  
684 with inhibitory activity on arachidonate 12-lipoxygenase, 15-lipoxygenase and leukotriene receptor  
685 antagonists. *Phyther. Res* 19(4):263–272. <https://doi.org/10.1002/ptr.1604>

686 Silva FA, Rodrigues BL, Ayrizono M de LS, Leal RF (2016) The immunological basis of inflammatory  
687 bowel disease. *Gastroenterol. Res. Pract* 2016:2097274. <https://doi.org/10.1155/2016/2097274>

688 Singh K, Jaggi AS, Singh N (2009) Exploring the ameliorative potential of *Punica granatum* in dextran  
689 sulfate sodium induced ulcerative colitis in mice. *Phyther. Res* 23(11):1565–1574.  
690 <https://doi.org/10.1002/ptr.2822>

691 Slattery ML, Benson J, Curtin K, Ma K-N, Schaeffer D, Potter JD (2000) Carotenoids and colon cancer.  
692 *Am. J. Clin. Nutr* 71(2):575–582. <https://doi.org/10.1093/ajcn/71.2.575>

693 Trivedi PP, Jena GB (2015) Mechanistic insight into beta-carotene-mediated protection against ulcerative  
694 colitis-associated local and systemic damage in mice. *Eur. J. Nutr* 54(4):639–652.  
695 <https://doi.org/10.1007/s00394-014-0745-5>

696 Valentão P, Fernandes E, Carvalho F, Andrade PB, Seabra RM, Bastos ML (2001) Antioxidant activity of  
697 Centaurium erythraea infusion evidenced by its superoxide radical scavenging and xanthine oxidase  
698 inhibitory activity. *J. Agric. Food Chem* 49(7):3476–3479.

699 Valero M, Berzosa C, Langa E, Gómez-Rincón C, López V (2013) Jasonia glutinosa D.C: botanical,  
700 phytochemical and pharmacological aspects. *Boletín Latinoam. y del Caribe Plantas Med. y Aromáticas*  
701 12(6):543–557.

702 Valero MS, Fagundes DS, Grasa L, Arruebo MP, Plaza MÁ, Murillo MD (2011) Contractile effect of  
703 tachykinins on rabbit small intestine. *Acta Pharmacol. Sin* 32(4):487–494.  
704 <https://doi.org/10.1038/aps.2010.227>

705 Valero MS et al (2015) Rock Tea extract (Jasonia glutinosa) relaxes rat aortic smooth muscle by inhibition  
706 of L-type Ca<sup>2+</sup> channels. *J. Physiol. Biochem* 71(4):785–793. [https://doi.org/10.1007/s13105-015-0442-](https://doi.org/10.1007/s13105-015-0442-8)  
707 8

708 Villaescusa-Castillo L et al (2000) Antiprotozoal activity of sesquiterpenes from Jasonia glutinosa. *Pharm.*  
709 *Biol* 38(3):176–180. [https://doi.org/10.1076/1388-0209\(200007\)3831-SFT176](https://doi.org/10.1076/1388-0209(200007)3831-SFT176)

710 Villaescusa L, Díaz A, Bartolomé C (1995) Methoxylated flavonoids from Jasonia glutinosa, D.C., and  
711 their relation with others species of Jasonia. *Pharmazie* 50(9):639–640.

712 Villaescusa L, Diaz A, Martin T, Gasquet M, Delmas F, Balansard G (1996) Preliminary screening of  
713 antiprotozoal activity of Jasonia glutinosa aerial parts. *Int. J. Pharmacogn* 34(4):303–304.  
714 <https://doi.org/10.1076/phbi.34.4.303.13231>

715 Whittem CG, Williams AD, Williams CS (2010) Murine colitis modeling using dextran sulfate sodium  
716 (DSS). *J. Vis. Exp* 35:1652. <https://doi.org/10.3791/1652>

717 Won K, Suzuki T, Hori M, Ozaki H (2006) Motility disorder in experimentally obstructed intestine:  
718 relationship between muscularis inflammation and disruption of the ICC network. *Neurogastroenterol.*  
719 *Motil* 18(1):53–61. <https://doi.org/10.1111/j.1365-2982.2005.00718.x>

720 Xiao H et al (2013) Inhibitory effect of the gallotannin corilagin on dextran sulfate sodium-induced murine  
721 ulcerative colitis. *J. Nat. Prod* 76(11):2120–2125. <https://doi.org/10.1021/np4006772>

722 Yazbeck R, Howarth GS, Butler RN, Geier MS, Abbott CA (2011) Biochemical and histological changes  
723 in the small intestine of mice with dextran sulfate sodium colitis. *J. Cell. Physiol* 226(12):3219–3224.  
724 <https://doi.org/10.1002/jcp.22682>

725 Zhang Z et al (2017) Chlorogenic acid ameliorates experimental colitis by promoting growth of  
726 Akkermansia in mice. *Nutrients* 9(7). <https://doi.org/10.3390/nu9070677>

727 Zheng K et al (2017) Traditional Chinese medicine combination therapy for patients with steroid-dependent  
728 ulcerative colitis: study protocol for a randomized controlled trial. *Trials* 18(1):8.  
729 <https://doi.org/10.1186/s13063-016-1763-9>

730

731

732 **Figure captions**

733

734 **Figure 1.** Representative HPLC-DAD chromatogram of the (a) phenolic compounds and (b) pigment  
735 profiles of *J. glutinosa* extract. Detection at 320 and 450 nm, respectively. (1) 3-*O*-caffeoylquinic acid; (2)  
736 5-*O*-caffeoylquinic acid; (3) 4-*O*-caffeoylquinic acid; (4) caffeic acid; (5) 1,3-di-*O*-caffeoylquinic acid; (6)  
737 Isoferulic acid; (7) 3,4-di-*O*-caffeoylquinic acid; (8) 3,5-di-*O*-caffeoylquinic acid; (9) 1,5-di-*O*-  
738 caffeoylquinic acid; (10) quercetin-3-*O*-galactoside; (11) quercetin-3-*O*-glucoside; (12) 4,5-di-*O*-  
739 caffeoylquinic acid; (13) quercetin; (14) kaempferol; (15) isorhamnetin; (16) chlorophyll *b*; (17) lutein; (18  
740 and 19) unidentified xanthophylls; (20 and 21) chlorophyll *a* derivatives; (22) pheophytin *a*; (23)  $\beta$ -  
741 carotene.

742

743 **Figure 2.** Antioxidant activities and anti-inflammatory effect in cell-free and cell-based assays. a)  
744 Antioxidant activity of RT extract and gallic acid against superoxide radicals generated by the  
745 xanthine/xanthine oxidase method. b) Xanthine oxidase inhibition by RT extract. c) Effect of *J. glutinosa*  
746 extract against  $O_2^{\bullet-}$  generated by the NADH/PMS system. d) Enzymatic inhibition of *J. glutinosa* extract  
747 towards 5-LOX. e) Effect of RT extract on production of nitrate concentration in LPS-stimulated cells (1  
748  $\mu$ g/ml). f) Inhibitory effect of RT in TNF- $\alpha$  expression in LPS-stimulated cells (1  $\mu$ g/ml). Results show  
749 mean  $\pm$  SEM of four or six experiments, each performed in triplicate. \*\* $P < 0.001$  vs. control group, # $P < 0.05$   
750 vs. LPS in absence of RT.

751

752 **Figure 3.** Induction and symptomatology of colitis. a) Experimental design of the induction of colitis by  
753 DSS administration for 7 days. Mice were daily treated with either RT extract (5, 25 or 50 mg/kg bw, p.o.),  
754 sulfasalazine (SSZ, 100 mg/kg bw), or vehicle over 20 days. From day 11 to day 17, mice received 2.5%  
755 dextran-sodium sulphate (DSS). At day 18, the drinking water with DSS was removed and three days of  
756 recovery were evaluated. b) The DAI score was assessed daily in all groups. Data are presented as mean  $\pm$   
757 SEM (n=4-15). \* $P < 0.05$ , \*\*\* $P < 0.001$  water+DSS group vs. control and RT<sub>50</sub> groups; & $P < 0.05$  RT<sub>5</sub>+DSS  
758 group vs control and RT<sub>50</sub> groups; § $P < 0.05$  RT<sub>25</sub>+DSS group vs control and RT<sub>50</sub> groups; ## $P < 0.01$ ,  
759 ### $P < 0.001$  RT<sub>50</sub>+DSS group vs control and RT<sub>50</sub> groups; ¶ $P < 0.05$ , ¶¶ $P < 0.001$  SSZ+DSS group vs. control  
760 and RT<sub>50</sub> groups. c) Comparison of the protective effect against colitis between RT<sub>50</sub> and SSZ. Data are  
761 presented as mean  $\pm$  SEM (n=8-15). \* $P < 0.05$ , \*\* $P < 0.01$  RT<sub>50</sub>+DSS group vs. water+DSS group; ¶ $P < 0.01$   
762 RT<sub>50</sub>+DSS vs. SSZ+DSS group.

763

764 **Figure 4.** Beneficial effects of RT extract on macroscopic and histopathological changes in the colon. a)  
765 Colon length. b) Macroscopic damage score. c) Proximal colon thickness. d) Distal colon thickness. Data  
766 are presented as mean  $\pm$  SEM (n=4-15). \* $P < 0.05$ , \*\*\* $P < 0.001$  vs. control group; # $P < 0.05$ , ## $P < 0.01$ ,  
767 ### $P < 0.001$  vs. RT<sub>50</sub> group; & $P < 0.05$ , && $P < 0.01$  vs. water+DSS group. e-h) Images of HE staining of distal  
768 colon on different groups: e) control group, f) water+DSS group, g) RT<sub>50</sub>+DSS group, h) RT<sub>50</sub> group (n=4).  
769 Scale bars represent 50  $\mu$ m (e, h) or 100  $\mu$ m (f, g).

770

771 **Figure 5.** Effects of RT extracts on alterations in intestinal contractility observed in colitis. a) Recordings  
772 of spontaneous contractions from longitudinal smooth muscle of mice ileum in different groups. b) Mean  
773 coefficient of variation of each longitudinal contraction in the ileum. c) Percentage of amplitude and d)  
774 frequency on spontaneous contractions. e) Effect of ACh (100  $\mu$ M) on spontaneous contractions. Data are  
775 expressed as mean  $\pm$  S.E.M. Segments obtained from 4-10 mice. \* $p$ <0.05 vs. control; # $p$ <0.05 and ## $p$ <0.01  
776 vs. RT<sub>50</sub> group

777

778 **Figure 6.** RT extract attenuates the inflammation and oxidant effect of DSS in colon from colitic mice. a)  
779 Colonic MPO activity, b) IL-6 levels and c) IL-10 levels in DSS-induced colitis. Representative western  
780 blots and quantitative analysis of d) iNOS protein and e) COX-2 protein. Data are presented as mean  $\pm$   
781 SEM (n=6-8). \* $P$ <0.05, \*\* $P$ <0.01 vs. control group; & $P$ <0.05, && $P$ <0.01 vs. water+DSS group.

782

783 **Figure 7.** Effect of RT extract on the expression of the tight junction protein ZO-1. Representative confocal  
784 images (n=3) on a) control group, b) water+DSS group and c) RT<sub>50</sub>+DSS group. In control mice (a), ZO-1  
785 was expressed at the luminal part of the epithelium (arrows) but an inner spherical staining was also  
786 observed (arrowheads). DSS decreased apical expression, effect reverted by RT<sub>50</sub> extract administration.  
787 M: mucosa. L: lumen.

**Table 1.** Phenolics and pigments content of *J. glutinosa* extract (mg/g dry extract)<sup>a</sup>

Peak	Compound	Regression equation ( $\mu\text{g/mL}$ )	$r^2$	Linearity ( $\mu\text{g/mL}$ )	LOD ( $\mu\text{g/mL}$ )	LOQ ( $\mu\text{g/mL}$ )	Precision		<i>J. glutinosa</i> (mg/g, dry extract)
							Inter-days (CV, %)	Intra-day (CV, %)	
<b><u>PHENOLIC COMPOUNDS</u></b>									
<b>Phenolic acids</b>									
1	3- <i>O</i> -Caffeoylquinic acid	$y = 2.063 \times 10^6 x$	0.9991	1.875-120.0	0.3230	0.9798	8.641	3.486	$0.9168 \pm 0.07921$
2	5- <i>O</i> -Caffeoylquinic acid	$y = 2.223 \times 10^6 x$	0.9994	0.2716-198.0	0.03256	0.09867	6.375	1.035	$12.32 \pm 0.7855$
3	4- <i>O</i> -Caffeoylquinic acid	$y = 2.116 \times 10^6 x$	0.9994	1.781-114.0	0.07630	0.2312	7.764	2.876	$0.6678 \pm 0.05185$
4	Caffeic acid	-	-	-	-	-	-	-	nq
5	1,3-di- <i>O</i> -caffeoylquinic acid	$y = 2.548 \times 10^6 x$	0.9995	0.4453-114.0	0.05592	0.1695	10.13	1.518	$0.5198 \pm 0.05263$
6	Isoferulic acid	$y = 3.921 \times 10^6 x$	0.9994	0.4296-110.0	0.03260	0.09888	10.06	7.057	$0.7829 \pm 0.07876$
7+8	3,4-di- <i>O</i> -caffeoylquinic acid + 3,5-di- <i>O</i> -caffeoylquinic acid <sup>b</sup>	$y = 2.455 \times 10^6 x$	0.9973	0.4805-246.0	0.03829	0.1160	6.418	7.527	$40.95 \pm 2.628$
9	1,5-di- <i>O</i> -caffeoylquinic acid	$y = 2.799 \times 10^6 x$	0.9999	0.4375-112.0	0.1322	0.4006	9.888	2.682	$24.73 \pm 2.445$
12	4,5-di- <i>O</i> -caffeoylquinic acid	$y = 2.537 \times 10^6 x$	1.000	0.4531-116.0	0.2527	0.7659	10.88	6.630	$23.14 \pm 2.516$
<b>Flavonoids</b>									
10	Quercetin-3- <i>O</i> -galactoside	$y = 1.832 \times 10^6 x$	0.9987	0.2908-212.0	0.08140	0.2467	8.219	1.695	$15.16 \pm 1.246$
11	Quercetin-3- <i>O</i> -glucoside	$y = 1.878 \times 10^6 x$	0.9992	0.07520-154.0	0.07796	0.2362	4.525	2.202	$7.716 \pm 0.3491$
13	Quercetin	$y = 1.907 \times 10^6 x$	0.9995	0.1387-124.0	0.08139	0.2466	8.149	1.189	$5.015 \pm 0.4087$
14	Kaempferol	$y = 1.941 \times 10^6 x$	0.9994	1.859-119.0	0.5339	1.6177	9.275	3.920	$0.5244 \pm 0.04864$
15	Isorhamnetin	$y = 6.322 \times 10^5 x$	0.9999	1.025-262.5	0.2252	0.6826	9.979	3.916	$1.983 \pm 0.2280$
<b>Total phenolics</b>									<b><math>134.4 \pm 10.92</math></b>

**Table 2. (continued)**

Peak	Compound	Regression equation ( $\mu\text{g/mL}$ )	$r^2$	Linearity ( $\mu\text{g/mL}$ )	LOD ( $\mu\text{g/mL}$ )	LOQ ( $\mu\text{g/mL}$ )	Precision		<i>J. glutinosa</i> (mg/g, dry extract)
							Inter-days (CV, %)	Intra-day (CV, %)	
<b>PIGMENTS</b>									
<b>Carotenoids</b>									
17	Lutein	$y = 2.492 \times 10^2 x$	0.9992	0.07813- 10.00	0.003416	0.01035	5.619	4.849	$0.1477 \pm 0.008299$
23	$\beta$ -carotene	$y = 6.713 \times 10^2 x$	1.000	0.2743- 66.67	0.03475	0.1053	9.129	5.548	$0.01953 \pm 0.001783$
<b>Chlorophylls</b>									
16	Chlorophyll <i>b</i>	$y = 9.459 \times 10^1 x$	0.9998	0.5208- 8.333	0.1027	0.3113	8.263	5.232	$0.09917 \pm 0.008194$
<b>Total pigments</b>									<b><math>0.2664 \pm 0.01828</math></b>

791 <sup>a</sup> Results are expressed as the mean  $\pm$  standard deviation of six determinations. LOD – limit of detection. LOQ – limit of quantification. <sup>b</sup> Quantified together as 3,5-  
792 dicaffeoylquinic acid. “nq” – not quantified